Our first target: breast conserving surgerySEE MORE
Worldwide over 1 million women diagnosed with breast cancer undergo BCT (surgery with follow-up radiotherapy) annually as an alternative to mastectomy, whereby both procedures result in comparable survival rate for early breast cancer.
The current standard of care recommending BCT suffers up to 15% recurrence rate within 10 years due to positive margin (residual cancer cells in the tumor bed after solid tumor removed).
5-years residual risks of recurrence for patients with stage I, II, III and IV cancers are about 7%, 11%, 13% and >20% respectively, relating to 5-years survival rate of 100%, 93%, 72% and 22% respectively.
Number of peer-reviewed scientific papers
Number of projects completed
Number of patents and patent pending
Number of conferences
Valérie has 14-yr experience in technology R&D, design and commercialization. She is co-inventor of NexPlasmaGen’s technology.
Audrey has 5-yr experience in conducting preclinical trials for breast and other cancers. She works at NexPlasmaGen and at the CR-CHUM.
Philip is an Assistant Professor at the Department of Radiation Oncology, University of Toronto. He is a clinician-investigator at the CR-CHUM. He leads NexPlasmaGen’s clinical program and is co-inventor of NexPlasmaGen’s technology.
Julie has 7-yr experience supervising Dr. Wong’s laboratory and plays a crucial role in NexPlasmaGen preclinical trials. She works at the CR-CHUM.
Valérie is currently the sole board member of NexPlasmaGen. New members will be added as we grow the company.
MDCM, MSc, FRCPC
Associate Professor, Department of Radiation Oncology, University of Toronto
Clinician-investigator-Princess Margaret Cancer Centre
M.D., Ph.D., FRCP(C)
IRIC Histology Platform Professor, Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal Anatomic-Pathologist, CHUM
Chief, Surgical Oncology Service, CHUM
Associate clinical professor, Department of Surgery, Faculty of Medicine, University of Montreal
Consultant, Regulatory and Clinical Affairs
VP, Medtech, General Inception-Venture Investments and Commercial Development
ex-BD Director, Covidien (Medtronic Minimally Invasive Therapies Group)
ex-BD Director, Hologic Inc.,
ex-BD VP at Bovie Medical
B.ScH, MD, FRCSI
EIR @ TIAP & Faculty of Medicine
Innovation Fellow at Women’s College
Managing Partner, Kettlebeck Ventures